Dyspareunia, signs of epithelial disruption, sexual abstinence, and HIV status in female sex workers in Nairobi: a cross-sectional study.
Anodyspareunia
Coital bleeding
Dyspareunia
Female sex workers (FSWs)
HIV infection risk
HIV key populations
Men who have sex with men (MSM)
Sexual dysfunction
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
16
03
2022
accepted:
28
08
2023
medline:
4
9
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
Epithelial trauma is a risk factor of HIV infection in men who have sex with men (MSM) and female sex workers (FSWs). Painful intercourse may be indicative of epithelial tissue disruption. Previous studies on a cohort of Kenyan FSWs established an association between prolonged sexual abstinence and late HIV seroconversion. Our research objective was to establish whether there is a relationship between HIV serostatus and signs of epithelial disruption and between HIV serostatus and sexual abstinence behaviour. Participants were selected from a Nairobi health facility. A structured questionnaire was administered to 322 FSWs, who provided data on HIV status, sexual behaviour, abstinence intervals and the level of sexual dysfunction. Sexual dysfunction scores were created using parts of the Female Sexual Function Index (FSFI-19). Additional questions addressed epithelial trauma signs. Descriptive data analysis, bivariate and multivariate logistic regression were used to describe the study population and determine factors associated with living with HIV. Potential factors influencing sexual dysfunction were assessed by FSWs via self-rating. 36% of FSWs reported discomfort or pain during vaginal penetration half the time. 44% noticed genital bleeding half the time. Vaginal tenderness was experienced by 70.6% half the time during or after intercourse. Variables predictive of living with HIV on multivariate analysis included a medium and high score of discomfort or pain during and following vaginal penetration (medium: AOR 2.288, p-value 0.032, 95% CI 1.075-4.871; high: AOR 3.044, p-value 0.031, 95% CI 1.110-8.348). No significant association of HIV status with past abstinence durations as reported by participants could be established in the multivariate analysis. A majority of FSWs agreed that steady partnerships (81% agreement), regularity of intercourse (74%), foreplay (72%) and lubricants (65%) alleviated dyspareunia. Recurrent exposure to blood during sex was highly prevalent in FSWs, as was sexual dysfunction. Complaint levels were associated with living with HIV, providing evidence that reducing sexual dysfunctions may prevent HIV transmission. Preventive initiatives may be created that address sexual dysfunction in key populations and general populations with a high HIV prevalence. Subjective assessments indicate that prevention may include the promotion of sexual intercourse regularity, foreplay, and lubricant use.
Sections du résumé
BACKGROUND
BACKGROUND
Epithelial trauma is a risk factor of HIV infection in men who have sex with men (MSM) and female sex workers (FSWs). Painful intercourse may be indicative of epithelial tissue disruption. Previous studies on a cohort of Kenyan FSWs established an association between prolonged sexual abstinence and late HIV seroconversion. Our research objective was to establish whether there is a relationship between HIV serostatus and signs of epithelial disruption and between HIV serostatus and sexual abstinence behaviour.
METHODS
METHODS
Participants were selected from a Nairobi health facility. A structured questionnaire was administered to 322 FSWs, who provided data on HIV status, sexual behaviour, abstinence intervals and the level of sexual dysfunction. Sexual dysfunction scores were created using parts of the Female Sexual Function Index (FSFI-19). Additional questions addressed epithelial trauma signs. Descriptive data analysis, bivariate and multivariate logistic regression were used to describe the study population and determine factors associated with living with HIV. Potential factors influencing sexual dysfunction were assessed by FSWs via self-rating.
RESULTS
RESULTS
36% of FSWs reported discomfort or pain during vaginal penetration half the time. 44% noticed genital bleeding half the time. Vaginal tenderness was experienced by 70.6% half the time during or after intercourse. Variables predictive of living with HIV on multivariate analysis included a medium and high score of discomfort or pain during and following vaginal penetration (medium: AOR 2.288, p-value 0.032, 95% CI 1.075-4.871; high: AOR 3.044, p-value 0.031, 95% CI 1.110-8.348). No significant association of HIV status with past abstinence durations as reported by participants could be established in the multivariate analysis. A majority of FSWs agreed that steady partnerships (81% agreement), regularity of intercourse (74%), foreplay (72%) and lubricants (65%) alleviated dyspareunia.
CONCLUSIONS
CONCLUSIONS
Recurrent exposure to blood during sex was highly prevalent in FSWs, as was sexual dysfunction. Complaint levels were associated with living with HIV, providing evidence that reducing sexual dysfunctions may prevent HIV transmission. Preventive initiatives may be created that address sexual dysfunction in key populations and general populations with a high HIV prevalence. Subjective assessments indicate that prevention may include the promotion of sexual intercourse regularity, foreplay, and lubricant use.
Identifiants
pubmed: 37658320
doi: 10.1186/s12879-023-08572-7
pii: 10.1186/s12879-023-08572-7
pmc: PMC10472738
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
569Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Sex Med. 2013 Dec;1(2):87-94
pubmed: 25356292
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
Cult Health Sex. 2010 Nov;12(8):929-42
pubmed: 20737330
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20227
pubmed: 26198350
PLoS Med. 2021 Jun 18;18(6):e1003670
pubmed: 34143779
Cult Health Sex. 2021 May;23(5):659-673
pubmed: 32212993
Immunol Lett. 1999 Mar;66(1-3):27-34
pubmed: 10203031
J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208
pubmed: 10782451
AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1072-1078
pubmed: 26879184
AIDS. 2010 Oct;24 Suppl 4:S15-26
pubmed: 21042049
Lancet. 1996 Nov 16;348(9038):1347-51
pubmed: 8918278
Top Antivir Med. 2019 Apr;27(1):8-25
pubmed: 31136999
BMC Womens Health. 2016 Mar 19;16:19
pubmed: 26992693
J Clin Invest. 2001 Feb;107(3):341-9
pubmed: 11160158
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
AIDS. 2014 Oct 23;28(16):2333-44
pubmed: 25389548
Epidemics. 2014 Sep;8:9-17
pubmed: 25240899
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25302
pubmed: 31328409
J Int AIDS Soc. 2021 Jun;24 Suppl 2:e25711
pubmed: 34164924
Pharmacotherapy. 2004 Jan;24(1):69-78
pubmed: 14740789
Lancet. 2012 Jul 28;380(9839):424-38
pubmed: 22819663
J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):66-82
pubmed: 21821552
Sex Transm Dis. 2011 Nov;38(11):1059-66
pubmed: 21992985
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):443-51
pubmed: 24815854
AIDS. 2001 May 25;15(8):1059-61
pubmed: 11399990
J Sex Marital Ther. 1998 Oct-Dec;24(4):281-92
pubmed: 9805288
J Sex Marital Ther. 2005 Mar-Apr;31(2):129-41
pubmed: 15859372
AIDS Behav. 2015 Feb;19 Suppl 1:S46-58
pubmed: 25428282
Gynecol Obstet Invest. 2000;50(1):54-9
pubmed: 10895030
Expert Opin Drug Deliv. 2022 Oct;19(10):1365-1380
pubmed: 36252277
Curr Opin HIV AIDS. 2010 Jul;5(4):305-10
pubmed: 20543605
Sex Transm Infect. 2013 Aug;89(5):366-71
pubmed: 23761166
Cult Health Sex. 2009 Apr;11(3):267-83
pubmed: 19173098
Afr J Reprod Health. 2004 Aug;8(2):55-8
pubmed: 15623118
Am J Public Health. 2010 Apr;100(4):714-9
pubmed: 20167895
PLoS One. 2010 Feb 09;5(2):e9119
pubmed: 20161749
AIDS Behav. 2008 Jul;12(4 Suppl):S78-85
pubmed: 18392672
Am J Epidemiol. 1996 Nov 1;144(9):817-27
pubmed: 8890660
Sex Transm Dis. 2006 Sep;33(9):551-7
pubmed: 16688100
Am J Public Health. 1987 Apr;77(4):479-83
pubmed: 3030146
Tissue Barriers. 2016 Mar 03;4(3):e1159276
pubmed: 27583187
J Int AIDS Soc. 2014 Feb 13;17:18845
pubmed: 24560342
Soc Sci Med. 1996 Jan;42(1):91-8
pubmed: 8745110
Int J STD AIDS. 2010 Jan;21(1):2-7
pubmed: 20029060
Am J Epidemiol. 1987 Oct;126(4):568-77
pubmed: 3651095
J Int AIDS Soc. 2019 Aug;22 Suppl 6:e25355
pubmed: 31468737
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):349-55
pubmed: 19387357
Sex Health. 2005;2(2):85-8
pubmed: 16342420
J Immunol. 2000 Feb 1;164(3):1602-11
pubmed: 10640781
AIDS Behav. 2019 Jun;23(6):1647-1655
pubmed: 30311105
Soc Sci Med. 1993 Oct;37(8):989-94
pubmed: 8235746
Am J Epidemiol. 1988 Oct;128(4):729-39
pubmed: 3421239
J Clin Invest. 1998 Nov 1;102(9):1758-65
pubmed: 9802890
Int J STD AIDS. 2018 Mar;29(4):367-374
pubmed: 28828904
Lancet. 2012 Jul 28;380(9839):367-77
pubmed: 22819660
Asian J Androl. 2013 Jul;15(4):545-9
pubmed: 23708455
Am J Reprod Immunol. 2013 Feb;69 Suppl 1:27-40
pubmed: 23176109
PLoS One. 2022 Oct 17;17(10):e0274288
pubmed: 36251657